Drugs / NUV-1511
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06334432 | Mar 2024 → Mar 2027 expected | Her2-receptor negative breast cancer, castration-resistant prostate carcinoma, malignant pancreatic neoplasm | Nuvation Bio Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-01-08 | Nuvation Bio Inc. | Regulatory Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors nuvationbio.com ↗
Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-1511, the first clinical candidate from the company’s novel drug-drug conjugate (DDC) platform. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-14 | Nuvation Bio Inc. | Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors nuvationbio.com ↗ |
| 2024-01-08 | Nuvation Bio Inc. | Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors nuvationbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NUV-1511 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06334432 ↗ |
| Modality | Small molecule | “Novel small molecule” NCT06334432 ↗ |